Ziprasidone_146939-27-7_DataSheet_MedChemExpress
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Product Name:
Ziprasidone CAS No.:
146939-27-7Cat. No.:
HY-14542Product Data Sheet
MWt:
412.94Formula:
C21H21ClN4OS Purity :>98%
Solubility:
DMSO
y Mechanisms:
Biological Activity:Ziprasidone(CP88059)is a combined 5HT (serotonin)and dopamine receptor antagonist which
Pathways:GPCR/G protein; Target:5-HT Receptor
Pathways:Neuronal Signaling; Target:5-HT Receptor
Pathways:GPCR/G protein; Target:Dopamine Receptor
Pathways:Neuronal Signaling;Target:Dopamine Receptor Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which
exhibits potent effects of antipsychotic activity.
IC50 value:
Target: 5-HT receptor; Dopamine receptor Ziprasidone possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential References:
[1]. Seeger, T.F., et al., Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and
serotonin receptor antagonist activity. J Pharmacol Exp Ther, 1995. 275(1): p. 101-13.[2]. Prakash, C., et al., Metabolism and excretion of a new antipsychotic drug, ziprasidone, in p yp y p p
[1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to
ziprasidone, ...
[]p y g p
humans. Drug Metab Dispos, 1997. 25(7): p. 863-72.[3]. Gao, K., et al., Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and
schizophrenia. J Clin Psychopharmacol, 2013. 33(3): p. 425-31.Caution: Not fully tested. For research purposes only
Medchemexpress LLC
18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。